Baek XX Chapter 62 ReleGland Pharma Q3 Result 2024: Date and Time, Share Price and Targetase Date

News: Gland Pharma, a leading pharmaceutical company, recently announced its Q3 results for the fiscal year 2024. Let’s dive into the key highlights and understand the company’s performance during this period.

Financial Snapshot

• Revenue from Operations: Gland Pharma reported revenue from operations at ₹1545.2 crores, marking a significant 65% YoY growth.
• EBITDA: The company’s EBITDA stood at ₹355.7 crores, reflecting a 23% YoY increase.
• Profit After Tax: Despite market fluctuations, Gland Pharma maintained a steady net profit of ₹191.9 crores, demonstrating resilience in challenging times.

Business Insights

• Market Segmentation:
  • US Market: Accounted for 53% of Q3FY24 revenue, down from 62% in Q3FY23.
  • Europe and ROW Market: Growth attributed to the acquisition of Cenexi.
  • Rest of the World Market: Contributed 18% of Q3FY24 revenue.
  • India Market: Accounted for 5% of Q3FY24 revenue.
• Research and Development (R&D):
  • Total R&D expenses for Q3 FY24 were ₹53 crores or 5% of operating revenue.
  • Filed 10 ANDA during the quarter and received approval for 3 ANDAs.
• Cenexi Performance:
  • Cenexi reported a revenue of ₹443.9 crores with a gross contribution of 75%.
  • EBITDA remained negative at ₹17 crores.

CEO’s Perspective

Mr. Srinivas Sadu, MD & CEO of Gland Pharma, expressed optimism:

“With strong results in the third quarter, we continued our positive momentum for the fiscal year. Our consolidated Q3 FY24 reported sales of INR 15,452 million, reflecting a quarter-on-quarter increase of 13% and a year-on-year increase of 65%. We achieved a consolidated EBITDA of INR 3,557 million and a consolidated net profit of INR 1,919 million.

Get the latest entertainment news with Sarkari Result! Be the first to know about celebrities and get thoughtful movie reviews. Stay connected with the fast-paced world of entertainment through Sarkari Exam.

Business Focus

Gland Pharma specializes in complex injectables, NCE-1s, First-to-File products, and 505(b)(2) filings. The company’s presence across the value chain has helped it witness exponential growth. Its professional management team, along with the support of global pharmaceutical major Shanghai Fosun Pharma, positions Gland Pharma as a key player in the pharmaceutical research, development, manufacturing, and marketing of injectables.

Global Reach

Gland Pharma’s reach extends to 60 countries, making it a reliable partner for healthcare providers worldwide. Its focus on innovation, quality, and affordability ensures that patients receive the best possible treatment.

Scientific Strategy

Gland Pharma’s scientifically curated strategy aims to deliver long-term value for employees, shareholders, and investors. By integrating research and development, manufacturing, and marketing, the company continues to make significant contributions to the pharmaceutical industry.

Gland Pharma’s robust financials and strategic moves position it well for future growth. Amid market volatility, the company’s focus on innovation and global expansion remains unwavering. Investors can look forward to a promising journey ahead.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.